Integromics Appoints Dr. Michael J. McManus as President & CEO
Integromics announced that it has selected Dr. Michael J. McManus as President & CEO. Dr. McManus will lead the company’s efforts to expand in the world market, with a particular focus on proteomics and on further developing Integromics’ activity in the U.S. and Asian markets.
Dr. McManus, 52, has over 25 years of scientific software and business experience, including operational management, business development, strategic planning, research and development, product marketing and product management expertise. His scientific background spans chemistry (including synthetic organic, computational, cheminformatics, and polymer chemistry sub-disciplines), bioinformatics, data mining and visualization. Dr. McManus received his Ph.D. in synthetic organic chemistry from the Massachusetts Institute of Technology. He received his B.S. in chemistry, summa cum laude, from the University of Massachusetts, Amherst.
Prior to joining Integromics, Dr. McManus led GenomeQuest’s corporate marketing, strategic alliances, product marketing and product development efforts. Before joining GenomeQuest, Dr. McManus served as Vice President of Business Development for the BioSciences Group of Fujitsu Computer Systems, where he set up and initiated the Group's U.S. operations and as Executive VP and COO of AnVil Informatics, Inc. Prior to AnVil, he served as Vice President of Marketing and Business Development at CambridgeSoft Corporation.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
8.5 million euros for innovative start-up teams to strengthen biotechnology in Bavaria - Bio M opens new start-up incubator
Evotec and Takeda enter into multi-year gene therapy research alliance
GxP Consulting Announces New Expansion Strategy into US and UK Markets
Fantastic muscle proteins and where to find them - “This is going to be unexpected even for myosin researchers”
Cancer Treatment with Built-in Light - Deep photodynamic therapy: photosensitizer irradiates itself
Silence Therapeutics Forms Scientific Advisory Board
InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways
Bayer Animal Health and Paraco agree on access to lead molecules
Wiggly proteins guard the genome - Dynamic network in the pores of the nuclear envelope blocks dangerous invaders
Defective immune cells in the brain cause Alzheimer’s disease - Scientists are studying the role of immune cell activation in Alzheimer's disease
Sepsis in Children: Improved Diagnosis Thanks to New Global Criteria - Researchers applied machine-learning methods to extrapolate from the data analysis evidence-based criteria for diagnosing
